Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.

Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):56-60. doi: 10.1016/j.bcmd.2014.02.006.

PMID:
24581483
2.

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.

Pastores GM, Rosenbloom B, Weinreb N, Goker-Alpan O, Grabowski G, Cohn GM, Zahrieh D.

Genet Med. 2014 May;16(5):359-66. doi: 10.1038/gim.2013.154.

3.

Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.

Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A.

Am J Hematol. 2013 Mar;88(3):166-71. doi: 10.1002/ajh.23381.

4.

Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.

Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA.

Am J Hematol. 2013 Mar;88(3):172-8. doi: 10.1002/ajh.23383.

5.

Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.

Elstein D, Foldes AJ, Zahrieh D, Cohn GM, Djordjevic M, Brutaru C, Zimran A.

Blood Cells Mol Dis. 2011 Jun 15;47(1):56-61. doi: 10.1016/j.bcmd.2011.04.005.

PMID:
21536468
6.

Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas.

Yoon SO, Zhang X, Freedman AS, Zahrieh D, Lossos IS, Li L, Choi YS.

Am J Pathol. 2010 Jul;177(1):377-86. doi: 10.2353/ajpath.2010.100048.

7.

CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.

Gunnarsdóttir KA, Jensen MB, Zahrieh D, Gelber RD, Knoop A, Bonetti M, Mouridsen H, Ejlertsen B.

Breast Cancer Res Treat. 2010 Aug;123(1):163-9. doi: 10.1007/s10549-010-0931-y.

8.

E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.

Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce CM, Gribben JG.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6250-5. doi: 10.1073/pnas.0901166106.

9.

A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data.

Bonetti M, Zahrieh D, Cole BF, Gelber RD.

Stat Med. 2009 Apr 15;28(8):1255-68. doi: 10.1002/sim.3524.

10.

A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.

Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N; IBCSG.; BIG.; NSABP..

Clin Breast Cancer. 2008 Jun;8(3):287-92. doi: 10.3816/CBC.2008.n.035.

PMID:
18650162
11.

Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group..

J Clin Oncol. 2008 Jun 20;26(18):3006-14. doi: 10.1200/JCO.2007.14.9336.

PMID:
18458044
12.

High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss.

Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA.

Genes Chromosomes Cancer. 2008 Jul;47(7):591-603. doi: 10.1002/gcc.20561.

PMID:
18383209
13.

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.

Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC.

Clin Cancer Res. 2008 Mar 1;14(5):1446-54. doi: 10.1158/1078-0432.CCR-07-4626.

14.

Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.

Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ.

Biol Blood Marrow Transplant. 2008 Feb;14(2):197-207. doi: 10.1016/j.bbmt.2007.10.010.

15.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.

Bernhard J, Zahrieh D, Zhang JJ, Martinelli G, Basser R, Hürny C, Forbes JF, Aebi S, Yeo W, Thürlimann B, Green MD, Colleoni M, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS; International Breast Cancer Study Group..

Br J Cancer. 2008 Jan 15;98(1):25-33.

16.

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A.

Ann Oncol. 2008 Mar;19(3):465-72.

PMID:
17986623
17.

Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis.

Wu CJ, Gladwin M, Tisdale J, Hsieh M, Law T, Biernacki M, Rogers S, Wang X, Walters M, Zahrieh D, Antin JH, Ritz J, Krishnamurti L.

Br J Haematol. 2007 Nov;139(3):504-7. No abstract available.

18.

Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy.

Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ, Alyea EP, Lee SJ.

Bone Marrow Transplant. 2007 Aug;40(3):209-17.

PMID:
17563734
19.

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.

Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S.

Cancer. 2007 May 1;109(9):1863-9.

20.

Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.

Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, Coates AS; International Breast Cancer Study Group Trial VIII..

J Clin Oncol. 2007 Jan 20;25(3):263-70. Erratum in: J Clin Oncol. 2007 Mar 20;25(9):1154.

PMID:
17159194
Items per page

Supplemental Content

Loading ...
Support Center